- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02816099
Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients (ApoC1)
Study of the Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesterol Ester Transfer Protein (CETP) in Type-1 Diabetes Patients
In type-1 diabetes patients, bad cholesterol tends to accumulate because apoC1 function is slowed down.
ApoC1 is a protein whose role is to diminish the activity of CETP, another protein that regulates cholesterol transfer in the body.
The aim of this study is to determine whether it is possible to correct apoC1 function by improving glycaemic balance.
240 persons will be recruited in this study and allocated to one of two groups:
160 Type-1 diabetes patients with uncontrolled diabetes:
- 4 additional blood samples will be taken at the time of the systematic biological examination at inclusion and then again 3 months later.
80 control subjects with normal lipids and normal glycaemia balance will be included in the study following the results of the biological assays.
- 4 blood samples will be taken at the time of inclusion.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Benjamin BOUILLET
- Phone Number: 33 03.80.29.34. 53
- Email: benjamin.bouillet@chu-dijon.fr
Study Locations
-
-
-
Besancon, France, 25030
- CHU de Besancon
-
Dijon, France, 21079
- CHU Dijon Bourgogne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria for patients:
- Patients over 18 years
- Patients with type-1 diabetes and glycated hemoglobin (HbA1C) >9%
Inclusion criteria controls:
- Subjects over 18 years
- Normal glycaemia (Fasting glycaemia <1.10 g/L) and normal lipids (Low-density lipoproteins (LDL) <1.6 g/L, triglycerides (TG) <1.5 g/L)
Exclusion Criteria:
Exclusion criteria patients:
- Adults under guardianship
- Patients without national health insurance
- Pregnant or breast-feeding women
- Progressive cancer
- Treatment able to influence lipoprotein metabolism (oestroprogestatives, immunosuppressants, long-term corticotherapy)
Exclusion criteria controls:
- Adults under guardianship
- Persons without national health insurance
- Pregnant or breast-feeding women
- known dyslipidemia and/or lipid-lowering treatment
- Treatment able to influence lipoprotein metabolism (oestroprogestatives, immunosuppressants, long-term corticotherapy)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Controls
|
|
Experimental: Type-1 diabetes patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparaison of linear correlation coefficients between plasma concentrations of apoC1 and CETP activity
Time Frame: 3 mois
|
3 mois
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BOUILLET AOI 2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on diabète de Type 1
-
Yale UniversityJuvenile Diabetes Research FoundationTerminatedType 1 Diabetes | De Novo LipogenesisUnited States
-
PETHEMA FoundationRecruitingLeukemia, Myeloid, Acute | De Novo | Age More 60yrSpain
-
Second Affiliated Hospital of Guangzhou Medical...Unknown
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Hadassah Medical OrganizationWithdrawnType 1 or 2 Diabetics
Clinical Trials on Prise de sang
-
Centre Hospitalier Universitaire DijonCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
China Medical University HospitalChina Medical University, China; Chang Gung Memorial Hospital; National Research...Unknown
-
Chang Gung Memorial HospitalChina Medical University, China; China Medical University Hospital; National... and other collaboratorsUnknown
-
Hacettepe UniversityCompletedConnective Tissue Graft HarvestingTurkey
-
Chinese University of Hong KongCompletedType 2 Diabetes | Acceptance and Commitment Therapy | Diabetes DistressHong Kong
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 1Germany
-
Universitaire Ziekenhuizen KU LeuvenKU Leuven; Stichting tegen KankerRecruitingSquamous Cell Carcinoma of Head and NeckBelgium
-
Santen Inc.CompletedDry EyeUnited States
-
Lund UniversityCompletedAortic Valve Disorder